Immunopathogenesis of Hepatitis B Virus

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic hepatitis B virus (HBV) infection is a major global health concern, leading to severe liver diseases and cancer in over 250 million individuals.
• HBV infection is noncytopathic; liver damage primarily results from host immune responses, which are often weak in chronic carriers.
• The virus evades early immune detection by rarely inducing type I interferon responses, complicating viral clearance.

Purpose of the Study:

• To review the immune response in acute and chronic hepatitis B.
• To evaluate current antiviral therapies and their limitations.
• To discuss the potential of immunotherapy for achieving a cure for chronic HBV infection.

Main Methods:

• Review of existing literature on HBV pathogenesis, immune responses, and treatment strategies.
• Analysis of the mechanisms of action for Interferon-α and nucleos(t)ide analogues.
• Discussion of the role of immunomodulators and immunotherapy in enhancing immune surveillance against HBV.

Main Results:

• Acute hepatitis B (AHB) involves effective innate and adaptive immune responses leading to viral clearance.
• Chronic hepatitis B (CHB) is characterized by weak immune responses, hindering viral clearance.
• Current therapies like Interferon-α and nucleos(t)ide analogues offer partial benefits but do not achieve complete seroclearance of HBV surface antigen.

Conclusions:

• Existing treatments for chronic HBV infection are suboptimal, with limited success in achieving viral eradication.
• Immunotherapy holds promise as a future strategy for HBV cure by inducing robust immune surveillance.
• Further research into immunomodulatory approaches is crucial for developing effective treatments for chronic hepatitis B.